CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA assessed indicators of commercially reasonable efforts using various industry data sources. CRA also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
CRA recognized in GAR’s ranking with the largest average claim size among top-10 expert firms
Global Arbitration Review’s Power Index identifies the most active and sought after expert firms in international arbitration. Every year, the GAR ranks the...